This company has been acquired
AERI Stock Overview
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aerie Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.25 |
| 52 Week High | US$15.37 |
| 52 Week Low | US$4.81 |
| Beta | -0.062 |
| 1 Month Change | 0.26% |
| 3 Month Change | 0.59% |
| 1 Year Change | 57.22% |
| 3 Year Change | -17.66% |
| 5 Year Change | -74.98% |
| Change since IPO | 43.73% |
Recent News & Updates
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13Shareholder Returns
| AERI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.1% | -2.4% | -3.4% |
| 1Y | 57.2% | -1.3% | 6.1% |
Return vs Industry: AERI exceeded the US Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: AERI exceeded the US Market which returned -21.7% over the past year.
Price Volatility
| AERI volatility | |
|---|---|
| AERI Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: AERI's share price has been volatile over the past 3 months.
Volatility Over Time: AERI's weekly volatility (10%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.
Aerie Pharmaceuticals, Inc. Fundamentals Summary
| AERI fundamental statistics | |
|---|---|
| Market cap | US$753.62m |
| Earnings (TTM) | -US$36.55m |
| Revenue (TTM) | US$213.94m |
3.5x
P/S Ratio-20.6x
P/E RatioIs AERI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AERI income statement (TTM) | |
|---|---|
| Revenue | US$213.94m |
| Cost of Revenue | US$23.52m |
| Gross Profit | US$190.42m |
| Other Expenses | US$226.98m |
| Earnings | -US$36.55m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 89.01% |
| Net Profit Margin | -17.09% |
| Debt/Equity Ratio | -190.6% |
How did AERI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/21 17:10 |
| End of Day Share Price | 2022/11/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aerie Pharmaceuticals, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Difei Yang | Brean Capital |
| John Newman | Canaccord Genuity |